Cargando…

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

Triple-negative breast cancer (TNBC) is a heterogeneous disease that can be classified into distinct molecular subtypes by gene expression profiling. Considered a difficult-to-treat cancer, a fraction of TNBC patients benefit significantly from neoadjuvant chemotherapy and have far better overall su...

Descripción completa

Detalles Bibliográficos
Autores principales: Lehmann, Brian D., Jovanović, Bojana, Chen, Xi, Estrada, Monica V., Johnson, Kimberly N., Shyr, Yu, Moses, Harold L., Sanders, Melinda E., Pietenpol, Jennifer A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911051/
https://www.ncbi.nlm.nih.gov/pubmed/27310713
http://dx.doi.org/10.1371/journal.pone.0157368
_version_ 1782438074897137664
author Lehmann, Brian D.
Jovanović, Bojana
Chen, Xi
Estrada, Monica V.
Johnson, Kimberly N.
Shyr, Yu
Moses, Harold L.
Sanders, Melinda E.
Pietenpol, Jennifer A.
author_facet Lehmann, Brian D.
Jovanović, Bojana
Chen, Xi
Estrada, Monica V.
Johnson, Kimberly N.
Shyr, Yu
Moses, Harold L.
Sanders, Melinda E.
Pietenpol, Jennifer A.
author_sort Lehmann, Brian D.
collection PubMed
description Triple-negative breast cancer (TNBC) is a heterogeneous disease that can be classified into distinct molecular subtypes by gene expression profiling. Considered a difficult-to-treat cancer, a fraction of TNBC patients benefit significantly from neoadjuvant chemotherapy and have far better overall survival. Outside of BRCA1/2 mutation status, biomarkers do not exist to identify patients most likely to respond to current chemotherapy; and, to date, no FDA-approved targeted therapies are available for TNBC patients. Previously, we developed an approach to identify six molecular subtypes TNBC (TNBCtype), with each subtype displaying unique ontologies and differential response to standard-of-care chemotherapy. Given the complexity of the varying histological landscape of tumor specimens, we used histopathological quantification and laser-capture microdissection to determine that transcripts in the previously described immunomodulatory (IM) and mesenchymal stem-like (MSL) subtypes were contributed from infiltrating lymphocytes and tumor-associated stromal cells, respectively. Therefore, we refined TNBC molecular subtypes from six (TNBCtype) into four (TNBCtype-4) tumor-specific subtypes (BL1, BL2, M and LAR) and demonstrate differences in diagnosis age, grade, local and distant disease progression and histopathology. Using five publicly available, neoadjuvant chemotherapy breast cancer gene expression datasets, we retrospectively evaluated chemotherapy response of over 300 TNBC patients from pretreatment biopsies subtyped using either the intrinsic (PAM50) or TNBCtype approaches. Combined analysis of TNBC patients demonstrated that TNBC subtypes significantly differ in response to similar neoadjuvant chemotherapy with 41% of BL1 patients achieving a pathological complete response compared to 18% for BL2 and 29% for LAR with 95% confidence intervals (CIs; [33, 51], [9, 28], [17, 41], respectively). Collectively, we provide pre-clinical data that could inform clinical trials designed to test the hypothesis that improved outcomes can be achieved for TNBC patients, if selection and combination of existing chemotherapies is directed by knowledge of molecular TNBC subtypes.
format Online
Article
Text
id pubmed-4911051
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-49110512016-07-06 Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection Lehmann, Brian D. Jovanović, Bojana Chen, Xi Estrada, Monica V. Johnson, Kimberly N. Shyr, Yu Moses, Harold L. Sanders, Melinda E. Pietenpol, Jennifer A. PLoS One Research Article Triple-negative breast cancer (TNBC) is a heterogeneous disease that can be classified into distinct molecular subtypes by gene expression profiling. Considered a difficult-to-treat cancer, a fraction of TNBC patients benefit significantly from neoadjuvant chemotherapy and have far better overall survival. Outside of BRCA1/2 mutation status, biomarkers do not exist to identify patients most likely to respond to current chemotherapy; and, to date, no FDA-approved targeted therapies are available for TNBC patients. Previously, we developed an approach to identify six molecular subtypes TNBC (TNBCtype), with each subtype displaying unique ontologies and differential response to standard-of-care chemotherapy. Given the complexity of the varying histological landscape of tumor specimens, we used histopathological quantification and laser-capture microdissection to determine that transcripts in the previously described immunomodulatory (IM) and mesenchymal stem-like (MSL) subtypes were contributed from infiltrating lymphocytes and tumor-associated stromal cells, respectively. Therefore, we refined TNBC molecular subtypes from six (TNBCtype) into four (TNBCtype-4) tumor-specific subtypes (BL1, BL2, M and LAR) and demonstrate differences in diagnosis age, grade, local and distant disease progression and histopathology. Using five publicly available, neoadjuvant chemotherapy breast cancer gene expression datasets, we retrospectively evaluated chemotherapy response of over 300 TNBC patients from pretreatment biopsies subtyped using either the intrinsic (PAM50) or TNBCtype approaches. Combined analysis of TNBC patients demonstrated that TNBC subtypes significantly differ in response to similar neoadjuvant chemotherapy with 41% of BL1 patients achieving a pathological complete response compared to 18% for BL2 and 29% for LAR with 95% confidence intervals (CIs; [33, 51], [9, 28], [17, 41], respectively). Collectively, we provide pre-clinical data that could inform clinical trials designed to test the hypothesis that improved outcomes can be achieved for TNBC patients, if selection and combination of existing chemotherapies is directed by knowledge of molecular TNBC subtypes. Public Library of Science 2016-06-16 /pmc/articles/PMC4911051/ /pubmed/27310713 http://dx.doi.org/10.1371/journal.pone.0157368 Text en © 2016 Lehmann et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Lehmann, Brian D.
Jovanović, Bojana
Chen, Xi
Estrada, Monica V.
Johnson, Kimberly N.
Shyr, Yu
Moses, Harold L.
Sanders, Melinda E.
Pietenpol, Jennifer A.
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
title Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
title_full Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
title_fullStr Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
title_full_unstemmed Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
title_short Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
title_sort refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911051/
https://www.ncbi.nlm.nih.gov/pubmed/27310713
http://dx.doi.org/10.1371/journal.pone.0157368
work_keys_str_mv AT lehmannbriand refinementoftriplenegativebreastcancermolecularsubtypesimplicationsforneoadjuvantchemotherapyselection
AT jovanovicbojana refinementoftriplenegativebreastcancermolecularsubtypesimplicationsforneoadjuvantchemotherapyselection
AT chenxi refinementoftriplenegativebreastcancermolecularsubtypesimplicationsforneoadjuvantchemotherapyselection
AT estradamonicav refinementoftriplenegativebreastcancermolecularsubtypesimplicationsforneoadjuvantchemotherapyselection
AT johnsonkimberlyn refinementoftriplenegativebreastcancermolecularsubtypesimplicationsforneoadjuvantchemotherapyselection
AT shyryu refinementoftriplenegativebreastcancermolecularsubtypesimplicationsforneoadjuvantchemotherapyselection
AT mosesharoldl refinementoftriplenegativebreastcancermolecularsubtypesimplicationsforneoadjuvantchemotherapyselection
AT sandersmelindae refinementoftriplenegativebreastcancermolecularsubtypesimplicationsforneoadjuvantchemotherapyselection
AT pietenpoljennifera refinementoftriplenegativebreastcancermolecularsubtypesimplicationsforneoadjuvantchemotherapyselection